Advertisement
Singapore markets closed
  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     
  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • FTSE 100

    7,860.49
    -16.56 (-0.21%)
     
  • Bitcoin USD

    64,147.42
    +335.16 (+0.53%)
     
  • CMC Crypto 200

    1,376.70
    +64.08 (+5.14%)
     
  • S&P 500

    4,991.14
    -19.98 (-0.40%)
     
  • Dow

    37,908.37
    +132.99 (+0.35%)
     
  • Nasdaq

    15,423.69
    -177.81 (-1.14%)
     
  • Gold

    2,401.70
    +3.70 (+0.15%)
     
  • Crude Oil

    82.92
    +0.19 (+0.23%)
     
  • 10-Yr Bond

    4.6250
    -0.0220 (-0.47%)
     
  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     
  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     
  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

Company News For Nov 1, 2017

Wall Street finished in the green reversing its five-day negative trend on Thursday following news that United States and China have ramped up their efforts to resolve lingering trade disputes
  • Shares of Pfizer Inc. PFE fell 0.3% after posting third quarter 2017 revenues of $13,168 million, below the Zacks Consensus Estimate of $13,169 million

  • Shares of Under Armour, Inc. UA plummeted almost 22% after posting third quarter 2017 earnings of $0.22 a share, lower than $0.29 a share in the year ago quarter

  • Shares of Aetna Inc. AET dipped 0.7% after posting third quarter 2017 revenues of $14,948 million, below the Zacks Consensus Estimate of $15,108 million

  • Shares of Acorda Therapeutics, Inc. ACOR declined 2.7% after posting third quarter 2017 revenues of $141 million, below the Zacks Consensus Estimate of $151 million


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pfizer, Inc. (PFE) : Free Stock Analysis Report
 
Acorda Therapeutics, Inc. (ACOR) : Free Stock Analysis Report
 
Aetna Inc. (AET) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research